Therapeutic Routes of Drug Administration in Chronic Obstructive Pulmonary Disease: Evidence-based Evaluation

Area of Science:

• Pulmonary Medicine
• Pharmacology
• Respiratory Therapeutics

Background:

• Chronic obstructive pulmonary disease (COPD) presents a significant global health challenge.
• Effective pharmacologic strategies are essential for managing COPD, with drug delivery optimization being key.
• Inhalation is the primary route for COPD pharmacotherapy, offering targeted lung delivery and reduced systemic effects.

Purpose of the Study:

• To review and compare the various pharmacologic strategies for COPD management.
• To evaluate the efficacy and limitations of different drug delivery routes in COPD treatment.
• To emphasize the importance of individualized route selection for optimizing patient outcomes in COPD.

Main Methods:

• Review of current literature on pharmacologic treatments for COPD.
• Analysis of different drug delivery modalities: inhalation (MDI, DPI, SMI, nebulizers), oral, parenteral, and transdermal.
• Evaluation of factors influencing treatment effectiveness, including patient technique and disease severity.

Main Results:

• Inhalation therapies are the mainstay for COPD maintenance, offering targeted delivery and fewer systemic side effects.
• Oral and parenteral routes have specific indications but are limited by adverse events and narrow therapeutic windows.
• Intravenous alpha-1 antitrypsin replacement and transdermal nicotine replacement therapy offer disease-modifying and supportive roles, respectively.

Conclusions:

• Inhalation remains the dominant and preferred route for COPD maintenance therapy.
• Systemic routes are reserved for severe exacerbations or specific patient populations.
• Optimal COPD management necessitates personalized drug delivery route selection based on individual patient factors and treatment objectives.